Skip to main content
Clinical Trials/NL-OMON52739
NL-OMON52739
Recruiting
Not Applicable

The search for biomarkers to enable detection and monitoring of disease progression from NAFLD to NASH and NASH itself; Amsterdam NASH cohort - Amsterdam NASH cohort (ANCHOR) study

Academisch Medisch Centrum0 sites300 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Academisch Medisch Centrum
Enrollment
300
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of steatosis hepatis on ultrasound or by biopsy or on Fibroscan
  • with CAP \>280dB/m
  • \>18 years of age
  • ASAT and/or ALAT levels above upper limit of normal in six months prior to
  • BMI \>25 kg/m2

Exclusion Criteria

  • Abusive alcohol use (\>20 IU/week)
  • Hepatitis B and/or C
  • Auto\-immune hepatitis
  • Wilsons disease/ alpha\-1\-antitripsine deficiency
  • Haemachromatose
  • Bleeding disorder, including the use of anticoagulant therapy and platelet
  • aggregation inhibitors. Except for subjects using platelet aggregation
  • inhibition monotherapy for the prevention of cardiovascular disease and without
  • a history of any coronary events. In this case the platelet aggregation
  • inhibitor will be discontinued for 7 days before the liver biopsy is performed.

Outcomes

Primary Outcomes

Not specified

Similar Trials